Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands

被引:13
|
作者
Freudenburg-de Graaf, W. [1 ,2 ]
Knol, M. J. [3 ]
van der Ende, A. [1 ,2 ]
机构
[1] Univ Amsterdam, Dept Med Microbiol & Infect Prevent, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands
[3] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control Netherlands, Bilthoven, Netherlands
基金
英国惠康基金;
关键词
Neisseria meningitidis; 4CMenB vaccine; Whole-genome sequencing; gMATS; B VACCINE; BACTERICIDAL ANTIBODIES; PERSISTENCE; AGE; IMMUNOGENICITY; IMMUNIZATION; ADOLESCENTS; INFANTS; STRAIN;
D O I
10.1016/j.vaccine.2020.10.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited. Recently, genomic MATS (Meningococcal Antigen Typing System) was developed as a tool to predict strain coverage, using vaccine antigens sequence data. We characterized all invasive meningococcal isolates received by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in two epidemiological years 2017-2019 using whole-genome sequencing and determined serogroup, clonal complex (cc) and estimated 4CMenB vaccine coverage by gMATS. Of 396 cases of invasive meningococcal disease, corresponding to an incidence of 1.22 cases/10(5) inhabitants, 180 (45%) were serogroup W, 155 (39%) serogroup B, 46 (12%) serogroup Y, 10 (3%) serogroup C, 2 non-groupable (0.5%) and 3 (0.7%) unknown. The incidence was the highest among 0-4 years olds (4 cases/10(5) inhabitants), and 57/72 (79%) of these cases were serogroup B. Serogroup W predominated among persons 45 years of age or older with 110/187 (59%) cases. Serogroup B isolates comprised 11 different clonal complexes, with 103/122 (84%) isolates belonging to 4 clonal complexes: cc32, cc41/44, cc269 and cc213. In contrast, serogroup W isolates were genetically similar with 95% belonging to ccl 1. Of 122 serogroup B isolates, 89 (73%; 95% CI: 64-80%) were estimated to be covered by 4CMenB and the degree of coverage varied largely by clonal complex and age. Among the 0-4 year olds, 25 of 43 (58%; 95% CI: 43-72%) MenB isolates were estimated to be covered. Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:7850 / 7857
页数:8
相关论文
共 50 条
  • [21] Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)
    Bettinger, Julie A.
    Scheifele, David W.
    Halperin, Scott A.
    Vaudry, Wendy
    Findlow, Jamie
    Borrow, Ray
    Medini, Duccio
    Tsang, Raymond
    VACCINE, 2013, 32 (01) : 124 - 130
  • [22] A new multicomponent vaccine (4CMenB) to protect against serogroup B invasive meningococcal disease. Part 1: Clinical data on the immunogenicity
    Zwiauer, K. F. M.
    Broker, M.
    Banzhoff, A.
    PADIATRIE UND PADOLOGIE, 2014, 49 : 3 - 12
  • [23] Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
    Ruiz Garcia, Yara
    Sohn, Woo-Yun
    Seib, Kate L.
    Taha, Muhamed-Kheir
    Vazquez, Julio A.
    de Lemos, Ana Paula S.
    Vadivelu, Kumaran
    Pizza, Mariagrazia
    Rappuoli, Rino
    Bekkat-Berkani, Rafik
    NPJ VACCINES, 2021, 6 (01)
  • [24] Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
    Ladhani, Shamez N.
    Andrews, Nick
    Parikh, Sydel R.
    Campbell, Helen
    White, Joanne
    Edelstein, Michael
    Bai, Xilian
    Lucidarme, Jay
    Borrow, Ray
    Ramsay, Mary E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (04): : 309 - 317
  • [25] Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
    Yara Ruiz García
    Woo-Yun Sohn
    Kate L. Seib
    Muhamed-Kheir Taha
    Julio A. Vázquez
    Ana Paula S. de Lemos
    Kumaran Vadivelu
    Mariagrazia Pizza
    Rino Rappuoli
    Rafik Bekkat-Berkani
    npj Vaccines, 6
  • [26] Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014
    Efron, Adriana
    Brozzi, Alessandro
    Biolchi, Alessia
    Bodini, Margherita
    Giuliani, Maria
    Guidotti, Silvia
    Lorenzo, Federico
    Moscoloni, Maria Alicia
    Muzzi, Alessandro
    Nocita, Florencia
    Pizza, Mariagrazia
    Rappuoli, Rino
    Tomei, Sara
    Vidal, Gabriela
    Vizzotti, Carla
    Campos, Josefina
    Sorhouet Pereira, Cecilia
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [27] Characteristics of YouTube videos about the meningococcal B vaccine (4CMenB)
    Hernandez-Garcia, Ignacio
    Ragozzino, Silvio
    Gimenez-Julvez, Teresa
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (10) : 2513 - 2517
  • [28] Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England
    Ladhani, Shamez N.
    Campbell, Helen
    Amin-Chowdhury, Zahin
    Lucidarme, Jay
    Borrow, Ray
    Ramsay, Mary E.
    VACCINE, 2022, 40 (10) : 1493 - 1498
  • [29] Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020
    Muzzi, Alessandro
    Lu, Min-Chi
    Mori, Elena
    Biolchi, Alessia
    Fu, Tiffany
    Serino, Laura
    MSPHERE, 2024, 9 (06)
  • [30] Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives
    Whelan, Jane
    Bambini, Stefania
    Biolchi, Alessia
    Brunelli, Brunella
    Holle, Mirna Robert-Du Ry van Beest
    EXPERT REVIEW OF VACCINES, 2015, 14 (05) : 713 - 736